drugset
drugset / Trial / NCT05710185

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

NCT05710185 ↗

Phase 4 Terminated 3 enrolled Brigham and Women's Hospital University of Pennsylvania · collab
NaSingle-groupOpen-labelTreatment

Summary

A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.

Timeline

Start
2023-07-01
Primary completion
2024-12-01
Completion
2025-01-31

Outcome

Outcome not reported

Stopped (Business): “Sponsor terminated funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule 6 mg —

Indications

palmoplantar pustulosis